Key facts
- AeroRx Therapeutics’s last known valuation is $48.0M (Oct 2025).
- It has raised $26.8M across 1 recorded rounds; the latest was Early Stage VC ($10.4M) in Sep 2025.
- Notable investors include Correlation Ventures, Alexandria Venture Investments, Prebys Ventures, Avalon Bioventures.
- AeroRx Therapeutics has filed 1 Form D with the SEC, most recently Oct 2025 ($10.4M sold to 17 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for AeroRx Therapeutics
Funding rounds
1 roundsAbout AeroRx Therapeutics
Developer of combination drug therapies intended for respiratory disease treatment. The company develops treatments delivered via nebulization, focusing on older patients with chronic obstructive pulmonary disease, enabling patients to receive more effective and targeted care.
- Sector
- Healthcare
- HQ
- La Jolla, CA, United States
- Founded
- 2022
- Website
- aerorxtx.com/
- Ownership
- Privately Held (backing)
AeroRx Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AeroRx Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AeroRx Therapeutics in its N-PORT filings yet. We sweep new filings monthly.